RelB is the NF-κB subunit downstream of NIK responsible for osteoclast differentiation

NF-κB inducing kinase (NIK) is required for osteoclastogenesis in response to pathologic stimuli, and its loss leads to functional blockade of both alternative and classical NF-κB caused by cytoplasmic retention by p100. We now show that deletion of p100 restores the capacity of NIK-deficient osteoclast (OC) precursors to differentiate and normalizes RelB and p65 signaling. Differentiation of NIK−/− precursors is also restored by overexpression of RelB, but not p65. Additionally, RelB−/− precursors fail to form OCs in culture, and this defect is rescued by re-expression of RelB, but not by overexpression of p65. To further support the role of RelB in OCs, we challenged RelB−/− mice with TNF-α in vivo and found a diminished osteoclastogenic response. We then examined tumor-induced osteolysis in both RelB−/− and NIK−/− mice by using the B16 melanoma model. Growth of tumor cells in the bone marrow was similar to WT controls, but the absence of either RelB or NIK completely blocked the tumor-induced loss of trabecular bone. Thus, the alternative NF-κB pathway, culminating in activation of RelB, has a key and specific role in the differentiation of OCs that cannot be compensated for by p65.

[1]  G. Ghosh,et al.  X-ray structure of a NF-kappaB p50/RelB/DNA complex reveals assembly of multiple dimers on tandem kappaB sites. , 2007, Journal of molecular biology.

[2]  K. Trinkaus,et al.  Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. , 2007, Blood.

[3]  A. Hoffmann,et al.  A c-Rel subdomain responsible for enhanced DNA-binding affinity and selective gene activation. , 2005, Genes & development.

[4]  David Piwnica-Worms,et al.  Real-time imaging of ligand-induced IKK activation in intact cells and in living mice , 2005, Nature Methods.

[5]  Osami Kanagawa,et al.  NF-κB–inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis , 2005 .

[6]  Georg Schett,et al.  IκB kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss , 2005, The Journal of experimental medicine.

[7]  S. Akira,et al.  Osteoclast Differentiation Is Impaired in the Absence of Inhibitor of κB Kinase α* , 2004, Journal of Biological Chemistry.

[8]  H. Strobl,et al.  RelB regulates human dendritic cell subset development by promoting monocyte intermediates. , 2004, Blood.

[9]  B. Aronow,et al.  Activation of IKKα target genes depends on recognition of specific κB binding sites by RelB:p52 dimers , 2004 .

[10]  Matthew J. Silva,et al.  Marrow Stromal Cells and Osteoclast Precursors Differentially Contribute to TNF-α-Induced Osteoclastogenesis In Vivo1 , 2004, The Journal of Immunology.

[11]  Sankar Ghosh,et al.  Signaling to NF-kappaB. , 2004, Genes & development.

[12]  Y. Abu-Amer,et al.  The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. , 2004, The Journal of biological chemistry.

[13]  Koji Okabe,et al.  Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo , 2004, Nature Medicine.

[14]  B. Rayet,et al.  Divergent C-terminal transactivation domains of Rel/NF-κB proteins are critical determinants of their oncogenic potential in lymphocytes , 2004, Oncogene.

[15]  C. Hunter,et al.  Cutting Edge: NF-κB2 Is a Negative Regulator of Dendritic Cell Function1 , 2004, The Journal of Immunology.

[16]  M. Tomasson,et al.  Platelet and osteoclast β3 integrins are critical for bone metastasis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Amer A. Beg,et al.  Regulation of Developing B Cell Survival by RelA-Containing NF-κB Complexes 1 , 2003, The Journal of Immunology.

[18]  David Baltimore,et al.  Genetic analysis of NF‐κB/Rel transcription factors defines functional specificities , 2003, The EMBO journal.

[19]  D. Goeddel,et al.  The IκB Function of NF-κB2 p100 Controls Stimulated Osteoclastogenesis , 2003, The Journal of experimental medicine.

[20]  S. Saccani,et al.  Modulation of NF-κB Activity by Exchange of Dimers , 2003 .

[21]  Y. Abu-Amer,et al.  Dominant-negative IκB Facilitates Apoptosis of Osteoclasts by Tumor Necrosis Factor-α* , 2003, Journal of Biological Chemistry.

[22]  N. Hacohen,et al.  Requirement for the NF-κB Family Member RelA in the Development of Secondary Lymphoid Organs , 2002, The Journal of experimental medicine.

[23]  P. Auberger,et al.  RelB reduces thymocyte apoptosis and regulates terminal thymocyte maturation , 2002, European journal of immunology.

[24]  F. Weih,et al.  Essential Role of RelB in Germinal Center and Marginal Zone Formation and Proper Expression of Homing Chemokines1 , 2001, The Journal of Immunology.

[25]  D. Baltimore,et al.  Targeted Mutation of TNF Receptor I Rescues the RelA-Deficient Mouse and Reveals a Critical Role for NF-κB in Leukocyte Recruitment1 , 2001, The Journal of Immunology.

[26]  Y. Abu-Amer.  IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-κB , 2001 .

[27]  D. Goeddel,et al.  Defective Lymphotoxin-β Receptor-Induced NF-κB Transcriptional Activity in NIK-Deficient Mice , 2001, Science.

[28]  Shi Wei,et al.  Receptor Activator of Nuclear Factor- B Ligand Activates Nuclear Factor- B in Osteoclast Precursors , 2001 .

[29]  Michael W.-H. Wang,et al.  Receptor Activator of Nuclear Factor-κB Ligand Activates Nuclear Factor-κB in Osteoclast Precursors. , 2001, Endocrinology.

[30]  M. Matsumoto,et al.  Abnormal Immune Function of Hemopoietic Cells from Alymphoplasia (aly) Mice, a Natural Strain with Mutant NF-κB-Inducing Kinase1 , 2000, The Journal of Immunology.

[31]  T. Honjo,et al.  Alymphoplasia (aly)-Type Nuclear Factor κB–Inducing Kinase (Nik) Causes Defects in Secondary Lymphoid Tissue Chemokine Receptor Signaling and Homing of Peritoneal Cells to the Gut-Associated Lymphatic Tissue System , 2000, The Journal of experimental medicine.

[32]  Yukio Nakamura,et al.  Genetic approaches in mice to understand Rel/NF-κB and IκB function: transgenics and knockouts , 1999, Oncogene.

[33]  C. Snapper,et al.  Nuclear Factor (NF)-κB2 (p100/p52) Is Required for Normal Splenic Microarchitecture and B Cell–mediated Immune Responses , 1998, The Journal of experimental medicine.

[34]  Ulrich Siebenlist,et al.  Requirement for NF-κB in osteoclast and B-cell development , 1997 .

[35]  J. Caamaño,et al.  Osteopetrosis in mice lacking NF-κB1 and NF-κB2 , 1997, Nature Medicine.

[36]  David Baltimore,et al.  Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB , 1995, Nature.

[37]  T. Maniatis,et al.  NF-κB: A lesson in family values , 1995, Cell.

[38]  F. Weih,et al.  Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB/Rel family , 1995, Cell.

[39]  P. Dobrzanski,et al.  Both N- and C-terminal domains of RelB are required for full transactivation: role of the N-terminal leucine zipper-like motif , 1993, Molecular and cellular biology.

[40]  P. Dobrzanski,et al.  RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B , 1992, Molecular and cellular biology.

[41]  山田 卓司.  Abnormal immune function of hemopoietic cells from alymphoplasia (aly) mice, a natural strain with mutant NF-κB-inducing kinase , 2001 .